[go: up one dir, main page]

SE9401091D0 - Alphavirus cDNA vectors - Google Patents

Alphavirus cDNA vectors

Info

Publication number
SE9401091D0
SE9401091D0 SE9401091A SE9401091A SE9401091D0 SE 9401091 D0 SE9401091 D0 SE 9401091D0 SE 9401091 A SE9401091 A SE 9401091A SE 9401091 A SE9401091 A SE 9401091A SE 9401091 D0 SE9401091 D0 SE 9401091D0
Authority
SE
Sweden
Prior art keywords
present
cdna
polynucleotide molecules
animal
desired products
Prior art date
Application number
SE9401091A
Other languages
English (en)
Inventor
Peter Liljestroem
Henrik Garoff
Original Assignee
Bioption Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9401091(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption Ab filed Critical Bioption Ab
Priority to SE9401091A priority Critical patent/SE9401091D0/sv
Publication of SE9401091D0 publication Critical patent/SE9401091D0/sv
Priority to JP7525612A priority patent/JPH09511143A/ja
Priority to PCT/SE1995/000343 priority patent/WO1995027044A1/en
Priority to AT95914666T priority patent/ATE268813T1/de
Priority to ES95914666T priority patent/ES2223051T3/es
Priority to CA002184261A priority patent/CA2184261A1/en
Priority to EP95914666A priority patent/EP0753053B1/en
Priority to DK95914666T priority patent/DK0753053T3/da
Priority to DE69533130T priority patent/DE69533130T2/de
Priority to AU21557/95A priority patent/AU699384B2/en
Priority to FI963860A priority patent/FI963860A0/sv
Priority to US09/061,912 priority patent/US6566093B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/123—Hepatitis delta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/52—Vector systems having a special element relevant for transcription encoding ribozyme for self-inactivation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
SE9401091A 1994-03-31 1994-03-31 Alphavirus cDNA vectors SE9401091D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors
AU21557/95A AU699384B2 (en) 1994-03-31 1995-03-30 Alphavirus cDNA vectors
DE69533130T DE69533130T2 (de) 1994-03-31 1995-03-30 VEKTOREN DER ALPHAVIRUS cDNA
AT95914666T ATE268813T1 (de) 1994-03-31 1995-03-30 Vektoren der alphavirus cdna
PCT/SE1995/000343 WO1995027044A1 (en) 1994-03-31 1995-03-30 ALPHAVIRUS cDNA VECTORS
JP7525612A JPH09511143A (ja) 1994-03-31 1995-03-30 アルファーウイルスｃＤＮＡベクター
ES95914666T ES2223051T3 (es) 1994-03-31 1995-03-30 Vectores de adnc de alfavirus.
CA002184261A CA2184261A1 (en) 1994-03-31 1995-03-30 Alphavirus cdna vectors
EP95914666A EP0753053B1 (en) 1994-03-31 1995-03-30 ALPHAVIRUS cDNA VECTORS
DK95914666T DK0753053T3 (da) 1994-03-31 1995-03-30 Alfavirus-cDNA-vektorer
FI963860A FI963860A0 (sv) 1994-03-31 1996-09-27 Alfavirus cDNA-vektorer
US09/061,912 US6566093B1 (en) 1994-03-31 1998-04-17 Alphavirus cDNA vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors

Publications (1)

Publication Number Publication Date
SE9401091D0 true SE9401091D0 (sv) 1994-03-31

Family

ID=20393495

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors

Country Status (12)

Country Link
US (1) US6566093B1 (sv)
EP (1) EP0753053B1 (sv)
JP (1) JPH09511143A (sv)
AT (1) ATE268813T1 (sv)
AU (1) AU699384B2 (sv)
CA (1) CA2184261A1 (sv)
DE (1) DE69533130T2 (sv)
DK (1) DK0753053T3 (sv)
ES (1) ES2223051T3 (sv)
FI (1) FI963860A0 (sv)
SE (1) SE9401091D0 (sv)
WO (1) WO1995027044A1 (sv)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
AU741747B2 (en) 1997-05-13 2001-12-06 University Of North Carolina At Chapel Hill, The Lentivirus-based gene transfer vectors
FI110323B (sv) 1997-06-02 2002-12-31 Timo Korpela Rekombinantkonstruktion för ökning av genexpression hos växter
JP3835669B2 (ja) * 1997-11-14 2006-10-18 サノフィ パスツ−ル リミテッド アルファウイルス・ベクター
EP1707633A1 (en) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
AU749345B2 (en) * 1997-11-14 2002-06-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
WO2001036640A2 (en) 1999-11-18 2001-05-25 Chiron Corporation Human fgf-21 gene and gene expression products
WO2001066595A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
ATE485059T1 (de) * 2001-03-27 2010-11-15 Univ New York Tumortherapie mit vektoren auf sindbis virus- basis
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
CA2460269C (en) 2001-09-06 2013-01-15 Alphavax, Inc. Alphavirus replicon vector systems
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
AU2003218162B2 (en) 2002-03-15 2009-10-29 The Curators Of The University Of Missouri Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20050221493A1 (en) * 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
US20040208848A1 (en) 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
NZ540657A (en) 2002-12-13 2006-09-29 Alphavax Inc High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine
WO2004085660A2 (en) 2003-03-20 2004-10-07 Alphavax, Inc. Improved alphavirus replicons and helper constructs
ES2327643T3 (es) 2003-07-11 2009-11-02 Alphavax, Inc. Vacunas contra citomegalovirus basadas en alfavirus.
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
KR101162970B1 (ko) * 2003-10-08 2012-07-12 테리온 바이오로직스, 인크. 변형된 ｃｅａ/ｂ7 벡터
EP1745074A2 (en) * 2004-04-29 2007-01-24 The University of North Carolina at Chapel Hill Methods and compositions for enhancing cell adhesion properties
WO2005113782A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
FI20040704A0 (sv) * 2004-05-21 2004-05-21 Ari Hinkkanen Användning av ett replikativt virus eller ett rekombinant därav inom terapin
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
AU2006302794B2 (en) 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
FR2887259B1 (fr) 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
AU2009248735B2 (en) * 2008-05-23 2015-08-20 Fit Biotech Oy Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
CL2008002322A1 (es) * 2008-08-07 2009-06-05 Univ Concepcion Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
EP2698635A3 (en) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
JP2022543423A (ja) 2019-08-09 2022-10-12 ナットクラッカー セラピューティクス， インコーポレイテッド 治療用組成物から材料を除去するための製造方法および装置
CN115197964A (zh) * 2021-04-12 2022-10-18 华南农业大学 一种改进型pSFV1载体及其制备方法与应用
CN113549652A (zh) * 2021-07-21 2021-10-26 华农（肇庆）生物产业技术研究院有限公司 SFV-helper质粒、pSFVCs-LacZ病毒样颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors

Also Published As

Publication number Publication date
AU699384B2 (en) 1998-12-03
WO1995027044A1 (en) 1995-10-12
FI963860A (sv) 1996-09-27
ES2223051T3 (es) 2005-02-16
CA2184261A1 (en) 1995-10-12
FI963860A0 (sv) 1996-09-27
AU2155795A (en) 1995-10-23
EP0753053B1 (en) 2004-06-09
ATE268813T1 (de) 2004-06-15
DE69533130D1 (de) 2004-07-15
EP0753053A1 (en) 1997-01-15
DK0753053T3 (da) 2004-10-11
US6566093B1 (en) 2003-05-20
JPH09511143A (ja) 1997-11-11
DE69533130T2 (de) 2005-07-07

Similar Documents

Publication Publication Date Title
DK0753053T3 (da) Alfavirus-cDNA-vektorer
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
DE69535376D1 (de) Expressionsvektor des alphavirus
IT7927940A0 (it) Estrattore chirurgico per asportare corpi estranei che si trovano nelle vie naturali del corpo umano, come calcoli e simili.
EP0365598A4 (en) Therapeutic antimicrobial polypeptides, their use and methods for preparation
ES557100A0 (es) Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
NO844579L (no) Enzymresistente immunomodulerende peptider.
ATE95060T1 (de) Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
ATE230985T1 (de) Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
TW200407425A (en) Human coagulation factor VII polypeptides
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
HUT40695A (en) Dna sequences, recombinant dna molecules and processes for preparing humane lipocortine like polypeptides
BR0213121A (pt) modelo in vitro para atividade priocidal
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DK1250422T3 (da) Myeloid-kolonistimulerende faktor og anvendelser deraf
Wodzicka-Tomaszewska et al. Interactions between stress and boar stimulation in induction of puberty in gilts.
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도